Drugs /

grt-r904

Back to Drugs List

Overview

NCI Definition [1]:
A cancer boosting vaccine consisting of tumor-specific shared neoantigens, which are immunogenic and unique across a subset of patients, with potential immunostimulating and antineoplastic activities. Upon administration of the neoantigen-based therapeutic cancer vaccine GRT-R904, which is administered after the initial administration of the priming vaccine GRT-C903, the peptides stimulate the host immune system to mount a specific cytotoxic T-lymphocyte (CTL) response against the shared neoantigens expressed on tumor cells, which results in tumor cell lysis.

Clinical Trials

View Clinical Trials for grt-r904

Grt-r904 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating grt-r904, 1 is phase 1/phase 2 (1 open).

BRAF G466V, CTNNB1 S37F, and CTNNB1 S45F are the most frequent biomarker inclusion criteria for grt-r904 clinical trials.

Colorectal carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in grt-r904 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Grt-R904
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating grt-r904 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
neoantigen-based therapeutic cancer vaccine grt-r904, grtr904, grt r904
NCIT ID [1]:
C165515

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.